Form 4: Rapport Therapeutics COO Cheryl Gault Reports Acquisition of 13,987 Shares

Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, reports the acquisition of 13,987 shares of common stock on March 3, 2025, according to a Form 4 filing.

Summary

• Cheryl Gault, the Chief Operating Officer of Rapport Therapeutics, filed a Form 4 with the SEC.
• The filing reports the acquisition of 13,987 shares of Rapport Therapeutics common stock on March 3, 2025.
• These shares were acquired at a price of $0.
• The acquisition increases Gault's direct ownership to 171,928 shares.
• The shares were granted as restricted stock units (RSUs) under the company's 2024 Stock Option and Incentive Plan.
• The RSUs vest in two equal annual installments following the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares by the COO is a potentially positive sign, but it's part of a compensation package.

Positives

• The acquisition of shares by a key executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The RSUs vest in two equal annual installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future performance.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule of two equal annual installments is a common practice for RSUs.

Key Dates